Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALRN Aileron Therapeutics		$2.52	$1.61 ▼ $4.40	$45.72M	2.24	81,731 shs	63,385 shs
ESPR Esperion Therapeutics	$0.99 -2.6%	$0.97	$0.69 ▼ $3.94	$196.93M	0.67	4.89 million shs	4.00 million shs
INBX Inhibrx Biosciences	$14.43 -2.4%	$13.10	$10.80 ▼ $17.79	$208.95M	N/A	96,808 shs	392,912 shs
INMB INmune Bio	$5.33 -15.1%	$7.42	$2.19 ▼ $11.64	$122.48M	1.55	575,375 shs	59.45 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALRN Aileron Therapeutics	0.00%	0.00%	0.00%	0.00%	-23.83%
ESPR Esperion Therapeutics	0.00%	-7.14%	+16.29%	-31.00%	-55.24%
INBX Inhibrx Biosciences	0.00%	-3.35%	+6.42%	+3.15%	+1.83%
INMB INmune Bio	0.00%	-16.46%	-28.55%	-31.75%	-39.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALRN Aileron Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	4.2776 of 5 stars	3.4	3.0	0.0	3.9	3.3	1.7	0.6
INBX Inhibrx Biosciences	1.5225 of 5 stars	0.0	1.0	0.0	4.6	2.0	1.7	1.3
INMB INmune Bio	2.0311 of 5 stars	3.6	0.0	0.0	0.0	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALRN Aileron Therapeutics	0.00	N/A	N/A	N/A
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	604.51% Upside
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A
INMB INmune Bio	3.17	Buy	$22.80	327.77% Upside

Current Analyst Ratings Breakdown

Latest ALRN, INMB, ESPR, and INBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/15/2025	INBX Inhibrx Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALRN Aileron Therapeutics	N/A	N/A	N/A	N/A	$1.41 per share	N/A
ESPR Esperion Therapeutics	$332.31M	0.59	$0.02 per share	41.35	($1.97) per share	-0.50
INBX Inhibrx Biosciences	$200K	1,044.73	$120.25 per share	0.12	$9.23 per share	1.56
INMB INmune Bio	$10K	12,248.34	N/A	N/A	$1.45 per share	3.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALRN Aileron Therapeutics	-$15.73M	-$3.12	0.00	N/A	N/A	N/A	-74.08%	-27.93%	N/A
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
INBX Inhibrx Biosciences	$1.69B	$116.75	0.12	N/A	N/A	N/A	-85.12%	-58.90%	8/12/2025 (Estimated)
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)

Latest ALRN, INMB, ESPR, and INBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2024	INBX Inhibrx Biosciences	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALRN Aileron Therapeutics	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALRN Aileron Therapeutics	N/A	3.30	3.30
ESPR Esperion Therapeutics	N/A	1.18	0.81
INBX Inhibrx Biosciences	1.04	5.12	5.12
INMB INmune Bio	N/A	2.64	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALRN Aileron Therapeutics	90.89%
ESPR Esperion Therapeutics	47.39%
INBX Inhibrx Biosciences	82.46%
INMB INmune Bio	12.72%

Insider Ownership

Company	Insider Ownership
ALRN Aileron Therapeutics	5.10%
ESPR Esperion Therapeutics	1.70%
INBX Inhibrx Biosciences	N/A
INMB INmune Bio	35.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALRN Aileron Therapeutics	9	21.67 million	20.56 million	Not Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
INBX Inhibrx Biosciences	166	14.48 million	N/A	Optionable
INMB INmune Bio	10	22.98 million	14.78 million	Optionable

ALRN, INMB, ESPR, and INBX Headlines

Recent News About These Companies

INmune Bio's US$24m Market Cap Fall Books Insider Losses

June 28 at 1:36 PM | finance.yahoo.com

INmune Bio Inc. (INMB) Stock Price Today - WSJ

June 28 at 3:34 AM | wsj.com

INmune Bio Stock Price, Quotes and Forecasts | NASDAQ:INMB - Benzinga

June 28 at 3:34 AM | benzinga.com

INmune Bio Stock (NASDAQ:INMB), Insider Trading Activity

June 27 at 10:33 PM | benzinga.com

INmune Bio Shares Pare Back Gains Following Direct Offering

June 27 at 5:33 PM | marketwatch.com

INmune Bio: Finding Pay Dirt In Alzheimer's?

June 27 at 5:01 PM | seekingalpha.com

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 27 at 12:16 PM | globenewswire.com

INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes

June 27 at 11:06 AM | benzinga.com

INMB - INmune Bio Inc News - Morningstar

June 27 at 5:46 AM | morningstar.comM

INmune Bio Climbs on Plan to Report Alzheimer's Study Data Monday

June 26, 2025 | marketwatch.com

Las acciones de INmune Bio se disparan antes de la publicación de datos sobre Alzheimer

June 26, 2025 | es.investing.com

INmune Bio put volume heavy and directionally bearish

June 26, 2025 | msn.com

INmune Bio stock soars ahead of Alzheimer’s trial data release

June 26, 2025 | za.investing.com

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th

June 26, 2025 | finance.yahoo.com

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th

June 26, 2025 | globenewswire.com

INmune Bio Target of Unusually Large Options Trading (NASDAQ:INMB)

June 21, 2025 | americanbankingnews.com

INmune Bio Target of Unusually High Options Trading (NASDAQ:INMB)

June 20, 2025 | marketbeat.com

INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity

June 16, 2025 | seekingalpha.com

INmune Bio, Inc. Collaborates on Study Showing XPro™ Treatment Reduces Alzheimer’s-like Pathology After Traumatic Brain Injury in Mice

June 12, 2025 | nasdaq.com

INmune Bio, Inc. (NASDAQ:INMB) Shares Bought by Two Sigma Investments LP

June 11, 2025 | marketbeat.com

Millennium Management LLC Boosts Stake in INmune Bio, Inc. (NASDAQ:INMB)

June 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALRN, INMB, ESPR, and INBX Company Descriptions

Aileron Therapeutics NASDAQ:ALRN

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

Esperion Therapeutics NASDAQ:ESPR

$0.99 -0.03 (-2.59%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.01 +0.01 (+1.35%)

As of 04:05 AM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Inhibrx Biosciences NASDAQ:INBX

$14.43 -0.36 (-2.43%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.32 -3.11 (-21.55%)

As of 04:00 AM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

INmune Bio NASDAQ:INMB

$5.33 -0.95 (-15.13%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.82 -2.51 (-47.07%)

As of 04:19 AM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time